Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort

Ankit K Desai, Carolyn H Baloh, John W Sleasman, Amy S Rosenberg, Priya S Kishnani, Ankit K Desai, Carolyn H Baloh, John W Sleasman, Amy S Rosenberg, Priya S Kishnani

Abstract

Immune tolerance induction (ITI) with a short-course of rituximab, methotrexate, and/or IVIG in the enzyme replacement therapy (ERT)-naïve setting has prolonged survival and improved clinical outcomes in patients with infantile Pompe disease (IPD) lacking endogenous acid-alpha glucosidase (GAA), known as cross-reactive immunologic material (CRIM)-negative. In the context of cancer therapy, rituximab administration results in sustained B-cell depletion in 83% of patients for up to 26-39 weeks with B-cell reconstitution beginning at approximately 26 weeks post-treatment. The impact of rituximab on serum immunoglobulin levels is not well studied, available data suggest that rituximab can cause persistently low immunoglobulin levels and adversely impact vaccine responses. Data on a cohort of IPD patients who received a short-course of ITI with rituximab, methotrexate, and IVIG in the ERT-naïve setting and had ≥6 months of follow-up were retrospectively studied. B-cell quantitation, ANC, AST, ALT, immunization history, and vaccine titers after B-cell reconstitution were reviewed. Data were collected for 34 IPD patients (25 CRIM-negative and 9 CRIM-positive) with a median age at ERT initiation of 3.5 months (0.1-11.0 months). B-cell reconstitution, as measured by normalization of CD19%, was seen in all patients (n = 33) at a median time of 17 weeks range (11-55 weeks) post-rituximab. All maintained normal CD19% with the longest follow-up being 248 weeks post-rituximab. 30/34 (88%) maintained negative/low anti-rhGAA antibody titers, even with complete B-cell reconstitution. Infections during immunosuppression were reported in five CRIM-negative IPD patients, all resolved satisfactorily on antibiotics. There were no serious sequelae or deaths. Of the 31 evaluable patients, 27 were up to date on age-appropriate immunizations. Vaccine titers were available for 12 patients after B-cell reconstitution and adequate humoral response was observed in all except an inadequate response to the Pneumococcal vaccine (n = 2). These data show the benefits of short-course prophylactic ITI in IPD both in terms of safety and efficacy. Data presented here are from the youngest cohort of patients treated with rituximab and expands the evidence of its safety in the pediatric population.

Keywords: alglucosidase alfa; anti-drug antibodies; anti-rhGAA IgG antibody; enzyme replacement therapy; immune tolerance induction; immunogenicity.

Copyright © 2020 Desai, Baloh, Sleasman, Rosenberg and Kishnani.

Figures

Figure 1
Figure 1
Longitudinal anti-rhGAA IgG antibody titers in IPD patients treated with immune tolerance induction. CRIM, cross-reactive immunologic material. CN, CRIM-negative; CP, CRIM-positive; ERT, enzyme replacement therapy; ITI, immune tolerance induction; SIT, sustained intermediate titer; HSAT, high and sustained antibody titer; rhGAA, recombinant human acid alpha-glucosidase.
Figure 2
Figure 2
Kaplan-Meler survival analysis: overall and invasive ventilator-free survival. CN, CRIM-negative; CP, CRIM-positive; ERT, enzyme replacement therapy; ITI, immune tolerance induction.

References

    1. Boustany RM. Lysosomal storage diseases–the horizon expands. Nat Rev Neurol. (2013) 9:583–98. 10.1038/nrneurol.2013.163
    1. Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. (2018) 4:27 10.1038/s41572-018-0037-0
    1. Sun A. Lysosomal storage disease overview. Ann Transl Med. (2018). 6:476. 10.21037/atm.2018.11.39
    1. Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. (2015) 23:1138–48. 10.1038/mt.2015.62
    1. Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet. (2012) 13:307–35. 10.1146/annurev-genom-090711-163739
    1. Bigger BW, Saif M, Linthorst GE. The role of antibodies in enzyme treatments and therapeutic strategies. Best Pract Res Clin Endocrinol Metab. (2015) 29:183–94. 10.1016/j.beem.2015.01.006
    1. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency. In: Valle D, Scriver CR, editors. Scriver's OMMBID the Online Metabolic & Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; (2009).
    1. Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, et al. . Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. (2006) 149:89–97. 10.1016/j.jpeds.2006.02.035
    1. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. . Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. (2007) 68:99–109. 10.1212/01.wnl.0000251268.41188.04
    1. Beck M. Alglucosidase alfa: long term use in the treatment of patients with Pompe disease. Ther Clin Risk Manag. (2009) 5:767–72. 10.2147/TCRM.S5776
    1. Do HV, Khanna R, Gotschall R. Challenges in treating Pompe disease: an industry perspective. Ann Transl Med. (2019) 7:291. 10.21037/atm.2019.04.15
    1. Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, et al. . The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. (2012) 14:800–10. 10.1038/gim.2012.44
    1. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. (2006) 148:671–6. 10.1016/j.jpeds.2005.11.033
    1. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, et al. . Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. (2009) 11:210–9. 10.1097/GIM.0b013e31819d0996
    1. Abbott MA, Prater SN, Banugaria SG, Richards SM, Young SP, Rosenberg AS, et al. . Atypical immunologic response in a patient with CRIM-negative Pompe disease. Mol Genet Metab. (2011) 104:583–6. 10.1016/j.ymgme.2011.08.003
    1. Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. . Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. (2010) 99:26–33. 10.1016/j.ymgme.2009.08.003
    1. Berrier KL, Kazi ZB, Prater SN, Bali DS, Goldstein J, Stefanescu MC, et al. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med. (2015) 17:912–8. 10.1038/gim.2015.6
    1. Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, et al. . Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. (2016) 117:66–83. 10.1016/j.ymgme.2015.11.001
    1. Kronn DF, Day-Salvatore D, Hwu WL, Jones SA, Nakamura K, Okuyama T, et al. . Disease newborn screening working, management of confirmed newborn-screened patients with pompe disease across the disease spectrum. Pediatrics. (2017) 140 (Suppl 1):S24–45. 10.1542/peds.2016-0280E
    1. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med. (2009) 360:194–5. 10.1056/NEJMc0806809
    1. Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, et al. . Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. (2012) 14:135–42. 10.1038/gim.2011.4
    1. Banugaria SG, Prater SN, Patel TT, Dearmey SM, Milleson C, Sheets KB, et al. . Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS ONE. (2013) 8:e67052. 10.1371/journal.pone.0067052
    1. Kazi ZB, Desai AK, Berrier KL, Troxler RB, Wang RY, Abdul-Rahman OA, et al. . Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight. (2017) 2:e94328. 10.1172/jci.insight.94328
    1. Desai AK, Kazi ZB, Bali DS, Kishnani PS. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. Mol Genet Metab Rep. (2019) 20:100475. 10.1016/j.ymgmr.2019.100475
    1. Desai AK, Li C, Rosenberg AS, Kishnani PS. Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review. Ann Transl Med. (2019) 7:285. 10.21037/atm.2019.05.27
    1. Poelman E, Hoogeveen-Westerveld M, Kroos-de Haan MA, van den Hout JMP, Bronsema KJ, van de Merbel NC, et al. . High sustained antibody titers in patients with classic infantile pompe disease following immunomodulation at start of enzyme replacement therapy. J Pediatr. (2018) 195:236–43 e3. 10.1016/j.jpeds.2017.11.046
    1. Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, et al. . B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. (2013) 163:847–54 e1. 10.1016/j.jpeds.2013.03.002
    1. Cronstein BN. Methotrexate BAFFles anti-drug antibodies. Nat Rev Rheumatol. (2018) 14:505–6. 10.1038/s41584-018-0064-y
    1. Bitoun S, Nocturne G, Ly B, Krzysiek R, Roques P, Pruvost A, et al. . Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann Rheum Dis. (2018) 77:1463–70. 10.1136/annrheumdis-2018-213403
    1. Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D'Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. (2017) 45:1128–34. 10.1111/apt.13994
    1. Sacco KA, Abraham RS. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy. (2018) 10:713–28. 10.2217/imt-2017-0178
    1. Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. (2014) 2:594–600. 10.1016/j.jaip.2014.06.003
    1. Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Rava L, et al. . B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol. (2016) 27:1811–22. 10.1681/ASN.2015050523
    1. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. . Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. (2003) 101:3857–61. 10.1182/blood-2002-11-3547
    1. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. . Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. (2006) 107:2639−42. 10.1182/blood-2005-08-3518
    1. Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab–for how long? J Allergy Clin Immunol. (2015) 136:1407–9. 10.1016/j.jaci.2015.06.035
    1. Kado R, Sanders G, McCune WJ. Suppression of normal immune responses after treatment with rituximab. Curr Opin Rheumatol. (2016) 28:251–8. 10.1097/BOR.0000000000000272
    1. Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant. (2008) 8:2607–17. 10.1111/j.1600-6143.2008.02411.x
    1. Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers. (2015) 7:305–28. 10.3390/cancers7010305
    1. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. (2003). 112:973–80. 10.1016/j.jaci.2003.07.003
    1. Lumizyme Package Insert Lumizyme R [Package Insert]. Cambridge, MA: Genzyme Corporation; (2016).
    1. Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, et al. . The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. (2011) 13:729–36. 10.1097/GIM.0b013e3182174703
    1. Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. . Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. (2012) 160C:40–9. 10.1002/ajmg.c.31319
    1. Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. . Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. (2012) 130 (3 Suppl.):S1–24. 10.1016/j.jaci.2012.07.002
    1. Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, et al. . Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. (2009) 66:329–35. 10.1203/PDR.0b013e3181b24e94
    1. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. . Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. (2001) 3:132–8. 10.1038/gim200127
    1. Kazi ZB, Desai AK, Troxler RB, Kronn D, Packman S, Sabbadini M, et al. . An immune tolerance approach using transient low-dose methotrexate in the ERT-naive setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. Genet Med. (2019) 21:887–95. 10.1038/s41436-018-0270-7
    1. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. . Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. (2009) 24:1321–8. 10.1007/s00467-009-1191-0
    1. Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, et al. . The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. (2015) 24:10–7. 10.1177/0961203314547793
    1. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. (2001) 358:1511–3. 10.1016/S0140-6736(01)06573-4
    1. Sellier-Leclerc AL, Macher MA, Loirat C, Guerin V, Watier H, Peuchmaur M, et al. . Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. (2010) 25:1109–15. 10.1007/s00467-010-1465-6
    1. Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. (2008) 50:822–5. 10.1002/pbc.21264
    1. Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. . Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. (2014) 83:142–50. 10.1212/WNL.0000000000000570
    1. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. (2011) 24:203–16. 10.1016/j.beha.2011.02.009
    1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. (1994) 83:435–45. 10.1182/blood.V83.2.435.bloodjournal832435
    1. Glaesener S, Quach TD, Onken N, Weller-Heinemann F, Dressler F, Huppertz HI, et al. . Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis. Arthritis Rheumatol. (2014) 66:2590–600. 10.1002/art.38736
    1. Ingelman-Sundberg HM, Laestadius A, Chrapkowska C, Mordrup K, Magnusson B, Sundberg E, et al. . Diverse effects on vaccine-specific serum IgG titres and memory B cells upon methotrexate and anti-TNF-alpha therapy in children with rheumatic diseases: a cross-sectional study. Vaccine. (2016) 34:1304–11. 10.1016/j.vaccine.2016.01.027
    1. Rackham OJ, Sills JA, Davidson JE. Immunoglobulin levels in methotrexate treated paediatric rheumatology patients. Arch Dis Child. (2002) 87:147–8. 10.1136/adc.87.2.147
    1. Yang CF, Yang CC, Liao HC, Huang LY, Chiang CC, Ho HC, et al. . Very early treatment for infantile-onset Pompe disease contributes to better outcomes. J Pediatr. (2016) 169:174–80 e1. 10.1016/j.jpeds.2015.10.078

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir